Forte Biosciences vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Forte Biosciences Inc (FBRX)

Q3 202621 Jul – 27 Aug 2026

▲2▼1

Forte acquired by argenx for $77/share after positive vitiligo data

Acquisition by argenx Forte Biosciences was acquired by argenx for $77 per share in cash, about $2.2 billion, an 86% premium. The deal closed August 27, 2026, giving shareholders the cash price.
This is the main event that drove FBRX's price in Q3 2026.
Positive Phase 1 vitiligo data Positive Phase 1 vitiligo data for FB102 made Forte an attractive takeover target, leading to the argenx acquisition and folding FB102 into argenx's immunology pipeline.
The clinical data was the catalyst that attracted the acquirer.
Investor-rights investigations Several investor-rights law firms are investigating whether $77 is fair, citing possible insider benefits and deal terms discouraging rival bids. Such probes rarely change an agreed cash deal.
This is the main risk that could affect the deal price or timing.
End of standalone trading With the buyout complete, FBRX no longer trades on its own clinical results. The stock's price is now tied to the cash deal, and future performance depends on argenx.
This marks the end of FBRX as an independent company, a key structural change.

August 202621 Jul – 27 Aug 2026

▲2

Forte Biosciences bought by argenx for $77 a share in cash

argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.
The agreed cash buyout is the single force that now determines FBRX's price.
Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.
Completion is the final event that locks in the buyout outcome for shareholders.
Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.
It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

Latest21 Jul – 27 Aug 2026

▲2

Forte Biosciences bought by argenx for $77 a share in cash

argenx agrees to buy Forte for $77/share cash argenx is acquiring Forte Biosciences for $77.00 per share in cash, a deal worth about $2.2 billion. That price is the main thing setting FBRX's value now: once a cash buyout is agreed, the stock tends to trade near the offer rather than on its own drug news.
The agreed cash buyout is the single force that now determines FBRX's price.
Deal closes, ending FBRX as a standalone stock argenx completed the acquisition on August 27, 2026, folding Forte's FB102 antibody into its immunology pipeline. Shareholders get the $77 cash per share. With the deal done, FBRX no longer trades on its own clinical results — its story is now argenx's pipeline plans.
Completion is the final event that locks in the buyout outcome for shareholders.
Law firms question whether $77 is fair Several investor-rights law firms are investigating whether the $77 sale is fair, citing possible insider benefits and deal terms that may discourage rival bids. They may seek a higher price or more disclosure. This creates some chance of a bump, but such probes rarely change an agreed cash deal.
It is the main counterweight to the buyout price and could affect what shareholders ultimately receive.

July 202623 Jul – 29 Jul 2026

▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

23 Jul – 29 Jul 2026

▲3

argenx's $2.2B cash buyout of Forte Biosciences drives FBRX

argenx to acquire Forte for $77/share cash argenx agreed to buy Forte for $77 per share in cash, about $2.2 billion, an 86% premium to Forte's recent average price. This puts a hard cash floor under the stock and is the main reason it jumped. Both boards approved the deal, expected to close in the third quarter of 2026.
This is the single new event that explains the period's move and sets the stock's value near the offer price.
Deal shifts focus to completion, not standalone growth With a buyer in place, FBRX now trades on whether the tender offer closes, not on its own drug pipeline. The stock sits just below the $77 offer, so the remaining gap is mostly deal-completion risk. That caps further upside unless a higher bid appears.
It tells readers what now drives the shares after the buyout, which is the key takeaway for anyone holding or considering FBRX.
Positive vitiligo data made Forte an attractive target Forte's FB102 showed positive Phase 1 vitiligo results earlier in July, which lifted the stock and helped attract argenx. The buyout price reflects a premium to the average price since that data, showing the trial success was a direct driver of the deal value.
It explains the underlying reason argenx wanted Forte and why the offer price is where it is.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.